Related Experiment Videos

[Clinical and bacteriological aspects of nocardiasis. 9 cases]

F Bani-Sadr1, M Hamidou, F Raffi

  • 1Service de Médecine interne Pr Grolleau, Hôtel-Dieu, Rouen.

Presse Medicale (Paris, France : 1983)
|June 24, 1995
PubMed

Insights

Nocardial infections can be localized or disseminated, particularly in immunocompromised individuals. Trimethoprim-sulfamethoxazole (TMP-SMX) remains the primary treatment, even when in vitro resistance is observed.

Area of Science:

  • Medical Microbiology
  • Infectious Diseases
  • Clinical Medicine

Background:

  • Nocardial infections present differently in immunocompetent versus immunocompromised patients.
  • Understanding treatment efficacy and antibiotic sensitivity is crucial for managing Nocardia infections.

Observation:

  • A retrospective study analyzed 9 cases of nocardial infections diagnosed between 1991 and 1994.
  • Six patients were immunocompromised, experiencing disseminated infections affecting lungs, brain, skin, and eyes.
  • Three immunocompetent patients presented with localized infections, including mycetoma and joint/lung involvement.

Findings:

  • Nocardia asteroides, N. farcinica, and N. caviae were identified.
  • In vitro antibiotic sensitivities varied, with amikacin and imipenem showing broad effectiveness.
  • Trimethoprim-sulfamethoxazole (TMP-SMX) was the most effective treatment, even in a case with in vitro resistance.

Implications:

  • TMP-SMX is confirmed as the gold standard for treating nocardial infections.
  • Clinical outcomes may not always align with in vitro antibiotic sensitivity data.
  • Further research into Nocardia treatment strategies is warranted.
Abstract

Related Concept Videos